Biogen Inc (BIIB.OQ) Quote| Reuters.com
Edition:
United States

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

229.02USD
24 Jun 2016
Change (% chg)

$-9.60 (-4.02%)
Prev Close
$238.62
Open
$232.00
Day's High
$235.19
Day's Low
$229.02
Volume
938,357
Avg. Vol
618,820
52-wk High
$417.59
52-wk Low
$229.02

BIIB.OQ

Chart for BIIB.OQ

About

Biogen Inc., formerly Biogen Idec Inc., is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA,... (more)

Overall

Beta: 0.97
Market Cap(Mil.): $50,167.17
Shares Outstanding(Mil.): 219.05
Dividend: --
Yield (%): --

Financials

  BIIB.OQ Industry Sector
P/E (TTM): 14.07 32.69 34.11
EPS (TTM): 16.28 -- --
ROI: 24.09 15.00 14.23
ROE: 33.60 16.08 15.46

S&P edges closer to record high; energy shares lead

The S&P 500 ended at its best level since July on Tuesday, helped by a big jump in energy shares and investor confidence that higher interest rates will not derail the economy. | Video

Jun 07 2016

US STOCKS-S&P edges closer to record high; energy shares lead

* Dow up 0.1 pct, S&P up 0.1 pct, Nasdaq down 0.1 pct (Updates to close)

Jun 07 2016

US STOCKS-S&P edges closer to record high; energy shares lead

* Dow up 0.3 pct, S&P up 0.3 pct, Nasdaq down 0.04 pct (Updates to late afternoon)

Jun 07 2016

US STOCKS-Oil, tech boost S&P and Dow, healthcare caps Nasdaq gains

* Indexes up: Dow 0.4 pct, S&P 0.19 pct, Nasdaq 0.04 pct (Updates to open)

Jun 07 2016

Biogen's MS drug misses main goal in mid-stage study

Biogen Inc's keenly watched experimental drug for treating multiple sclerosis failed to meet the main goal of improving some symptoms in a mid-stage study, sending the company's shares down as much as 9 percent in premarket trading.

Jun 07 2016

UPDATE 2-Biogen's MS drug misses main goal in mid-stage study

June 7 Biogen Inc's keenly watched experimental drug for treating multiple sclerosis failed to meet the main goal of improving some symptoms in a mid-stage study, sending the company's shares down as much as 9 percent in premarket trading.

Jun 07 2016

Biogen's MS drug misses main goal in mid-stage study

June 7 Biogen Inc said its experimental drug for treating multiple sclerosis, a nervous system disease affecting the brain and the spinal cord, did not meet the main goal of improving some symptoms in a mid-stage study.

Jun 07 2016

BRIEF-Biogen's Alzheimer drug Aducanumab Accepted into EMA's PRIME Program

* Biogen's Investigational Alzheimer's Disease Treatment Aducanumab Accepted Into European Medicines Agency's Prime Program

Jun 01 2016

Biogen, AbbVie once-monthly MS injection wins U.S. approval

The U.S. Food and Drug Administration on Friday approved a once-monthly injection for multiple sclerosis from Biogen Inc and AbbVie Inc, with a boxed warning.

May 27 2016

UPDATE 1-Biogen, AbbVie once-monthly MS injection wins U.S. approval

May 27 The U.S. Food and Drug Administration on Friday approved a once-monthly injection for multiple sclerosis from Biogen Inc and AbbVie Inc, with a boxed warning.

May 27 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Stock Traders Daily
$20.00
Provider : S&P Capital IQ – STARS Reports
$127.00
Provider : Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.